Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

Recruiting in Palo Alto (17 mi)

Overseen ByEugenio Cersosimo, MD,PhD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: The University of Texas Health Science Center at San Antonio

Prior Safety Data

Breakthrough Therapy

Approved in 5 jurisdictions

Trial Summary

What is the purpose of this trial?In this study, the researchers hope to learn about SGLT2 inhibition on EGP (endogenous glucose production) and plasma glucose concentration in diabetic subjects. Researchers will examine diabetes and the role of increased plasma glucagon, decline in plasma insulin, and fall in plasma glucose concentration.

Eligibility Criteria

Participant Groups

4Treatment groups

Active Control

Placebo Group

Group I: DapagliflozinActive Control1 Intervention

4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg

Group II: Byetta / BydureonActive Control1 Intervention

Exenatide: 4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc

Group III: Byetta/Bydureon plus DapagliflozinActive Control2 Interventions

Exenatide: 4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc PLUS Dapagliflozin: 4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg

Group IV: PlaceboPlacebo Group1 Intervention

Placebo group (4 weeks and 12 weeks)

Exenatide is already approved in United States, United States, United States, European Union, European Union for the following indications:

🇺🇸 Approved in United States as Byetta for: